BlinkBio, Inc. employs specialized Bioorthogonal chemistries for the delivery of next generation medicines for the treatment of cancer and other diseases. BlinkBio has optimized their proprietary chemistries into two types of novel linkers: one that allows the improved targeting of cytotoxic cancer medicines designed to rapidly kill cancer cells (so called Small Molecule Drug Conjugates (SMDCs) and Antibody Drug Conjugates (ADCs)); and the other that designs larger self-assembling therapeutics to target important cancer genes (such as MYC and p53) which exist inside cells and are not addressable using more traditional cancer therapeutics.
